TTX-MC138

DB18628InvestigationalGene Therapies

TTX-MC138 is an antisense oligonucleotide targeting miR-10b. It is under investigation for the treatment of various metastatic cancers.

Code names
TTX-MC138

What you can answer from here — as of April 23, 2025

3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of TTX-MC138, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In